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HDAC inhibitorsActivation of microglia is a common denominator and a pathophysiological hallmark of the central nervous sys-
tem (CNS) disorders. Damage or CNS disorders can trigger inflammatory responses in resident microglia and ini-
tiate a systemic immune system response. Although a repertoire of inflammatory responses differs in those
diseases, there is a spectrum of transcriptionally activated genes that encode various mediators such as growth
factors, inflammatory cytokines, chemokines, matrix metalloproteinases, enzymes producing lipid mediators,
toxic molocules, all of which contribute to neuroinflammation. The initiation, progression and termination of in-
flammation requires global activation of gene expression, postranscriptional regulation, epigeneticmodifications,
changes in chromatin structure and these processes are tightly regulated by specific signaling pathways. This re-
view focuses on the function of “master regulators” and epigenetic mechanisms in microglia activation during
neuroinflammation. We review studies showing impact of epigenetic enzyme inhibitors on microglia activation
in vitro and in vivo, and critically discuss potential of such molecules to prevent/moderate pathological events
mediated bymicroglia under brain pathologies. This article is part of a Special Issue entitled: Neuro Inflammation
edited by Helga E. de Vries and Markus Schwaninger.
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1.1. Microglia are instigators of neuroinflammation
Microglia are the innate immune cells in the central nervous system
(CNS). Microglia actively survey the CNS microenvironment [118] and
maintain homeostasis [47] under normal physiological conditions and
participate in the inflammatory response [93]. Microglia contribute to
normal CNS function by mechanisms such as fine tuning of neural
circuits [115] and phagocytosis of apoptotic debris [116]. Microglia are
highly reactive to insult or injury. The classical M1 type activation is
associated with cytotoxicity and inflammatory responses, whilst the
alternative activation M2 type is regarded as being beneficial, and can
be further subdivided into M2a, involved in repair and regeneration, the
immunoregulatory M2b, and an acquired-deactivation M2c type [23].
Activation of microglia is a common denominator and a pathophysio-
logical hallmark of virtually all neurodegenerative disorders. CNS infec-
tions, massive trauma, post-ischemic or toxicity-related necrosis,
hemorrhage or accumulation of neurotoxic fibers can trigger inflammato-
ry responses in resident microglia. Inflammation is a feature of several
neurodegenerative diseases, such as Alzheimer's disease (AD),
Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) andmultiple
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chronic phases [13]. Inflammatory stimuli activate microglia, which re-
lease inflammatory cytokines and phagocyte debris and dead cells, in an
attempt to initiate tissue repair and, thus, resolve the inflammatory pro-
cess. However, if the resolution mechanisms fail or the inflammatory
stimulus persists, there is a self-propagating and persistent stage of
chronic inflammation, which leads to neurotoxicity and neuronal death
[13,22]. Although a repertoire of inflammatory responses differs in vari-
ous diseases, there is a spectrum of transcriptionally activated genes
which encode various endogenousmediators such as growth factors, in-
flammatory cytokines interleukin 1 (IL-1β), tumor necrosis factor (TNF)-
α, interleukin (IL)-6, chemokines Fractalkine (CX3CL1), Macrophage In-
flammatory Factor (MIP)-1/CCL3, IL-8, matrix metalloproteinases
(MMPs), enzymes producing lipid mediators, nitric oxide and free radi-
cals, all of which contribute to neuroinflammation [1,39,71,98].
Despite different etiology of brain diseases associated to neuroinflam-
mation there are several primary triggers which are recognized by an
array of receptors on microglia. After an ischemic insult, damaged neu-
rons release different molecules: ATP, heat shock protein (HSP), adenine
dinucleotide (NAD), hyaluronic acid and fibronectin produced by extra-
cellular matrix degradation, nucleic acids, mannose residues proteolytic
enzymes and high-mobility group box 1 protein (HMGB1) [84,106].
DAMPs activate immune cells, including microglia [65] which release
pro-inflammatory cytokines toxic to already vulnerable neurons [136].
Excessive neuronal release of glutamate, which directly contributes to
neuronal death, activates microglia expressing metabotropic glutamate
receptors [154,155,112]. Damaged or overactive neurons release or leak
purines, including ATP and UTP that activate corresponding receptors.
Surveying microglia show a constitutive expression of most receptors
(P1 adenosine, P2 ionotropic P2X and metabotropic P2Y receptors) but
alter their set of purinergic receptors upon activation. Microglial activa-
tion and morphological transformation into amoeboid phagocytic cells
after damage require mostly P2Y12 and A3 receptors; A2A receptors in-
duce amoeboid transformation, P2Y12, P2X4, and A1 receptors interact to
induce recruitment to lesion site [90]. The damage signals released
from injured cells are collectively called danger-associated molecular
patterns (DAMPs) and are recognized and bind by pattern recognition
receptors (PRRs).
1.2. TLRs and cytokine signaling in microglia activation upon
neuroinflammation
1.2.1. Signaling via Toll-like receptors (TLR) in inflammatory microglia
Toll like receptors (TLRs) recognize a wide variety of danger signals
and consequently activate inflammatory cascades [43]. TLRs (with the ex-
ception of TLR3) initiate intracellular signaling via recruitment of the in-
tracellular adaptor proteins containing intracellular Toll-IL-1 receptor
(TIR) domain. These adaptors include: MyD88 (myeloid differentiation
factor 88); TIRAP (TIR-domain-containing adaptor protein), TRIF (TIR-do-
main-containing adaptor protein inducing IFN-β), and TRAM (TRIF-relat-
ed adaptormolecule), and can be differentially recruited to the TLR or IL-1
receptors and determine the specificity of signaling (Fig. 1A).
Toll-IL-1 receptors recruit an intracellular adaptor protein MyD88
(myeloid differentiation factor 88) containing TIR domain. When
MyD88 or other adaptors are recruited to activated TLRs, either directly
(TLRs 5 and 11) or indirectly (TLRs 1, 2, 4, 6), MyD88 engagesmembers
of the IRAK (IL-1R-associated kinase) family, to perform auto- and
cross-phosphorylation. Phosphorylated IRAKs dissociate from MyD88,
and bind TRAF6 (TNF receptor-associated factor 6) and ubiquitin E3 li-
gases. TRAF6 activates TAK1 (transforming growth factor β-activated
kinase) which activates the IKK complex and MAPKK (mitogen activat-
ed kinase kinases) as shown in the Fig. 1. The IKK complex phosphory-
lates IκB proteins which is necessary for the ubiquitination and
proteosomal degradation of IκBs and the subsequent nuclear transloca-
tion of the transcription factor NF-κB [76,77]. Members of the MAPK
family phosphorylate and activate components of the transcriptionfactor AP-1. The endosomal receptors TLR7 and TLR9 can recruit
MyD88 which further activates members of the IRAK family that bind
TRAF3. Activation of TRAF3 leads to phosphorylation and activation of
the interferon responsive factors: IRF3, IRF5, and IRF7. The endosomal
TLR3 recruits the Toll-interleukin 1 receptor domain-containing adaptor
inducing interferon β (TRIF) which binds kinases TBK1 and IKKε, which
activate IRF3. Further, TRIF recruits TRAF6 and RIP-1, which results in
activation of MAPK and IKKα/β [76,77].
TLRs and their downstream signaling molecules control microglial
behavior during neurodegeneration. TLR4 defects reduced levels of
TNFα, IL-1β, IL-10 and IL-17 in the brains of APP (APPswe/PSEN1)-
mice [68], diminished amyloid β (Aβ)-induced IL-1β, CCL3, and CCL4
expression in monocytes, reduced microglia activation and increased
Aβ deposits which was associated with impairment in cognitive func-
tions [145]. TLR2 deficiency (TLR2-KO) in APPswe/PSEN1 mice in-
creased soluble Aβ in the brain and exacerbated cognitive
impairments [132]. MyD88 deficiency reduced brain amyloid β
pathology and microglial activation [103,145], although a recent
observation using same transgenic mice showed that MyD88 signaling
does not significantly affect Aβ-induced microglial activation and cere-
bral Aβ-deposits [168]. Reconstitution of the immune system of irradi-
ated APP(swe)/PSEN1 mice with MyD88-deficient cells significantly
accelerated memory deficits [113]. In a cellular model of PD, microglia
cultured from TLR2 KO mice or cells treated with blocking antibody
against TLR2a showed reduced production of inflammatory mediators
after the exposure to the conditionedmedia from SH-SY5Y cells overex-
pressing human α-synuclein. These data implicate TLR2 as a receptor
for α-synuclein released from damaged neurons, responsible for
microglial activation observed in PD [89].
A growing body of evidence shows that TLRs and their downstream
signalingmolecules modulatemicroglial responses during acute neuro-
inflammation induced by nerve transection injury, intracerebral ische-
mia and hemorrhage, traumatic brain injury, and hippocampal
excitotoxicity [45]. TLR-4 deficiency protected mice against ischemia
and retinal ganglion cell axotomy-induced degeneration [86]. TLR4-
deficientmice had smaller cerebral ischemia–reperfusion injury and re-
duced TNF-α and IL-6 levels [45]. Further studies revealed that TLR4-KO
(but not TLR3- or TLR9-KO) mice had reduced infarct area in a middle
cerebral artery occlusion (MCAo) model. TLR4 was expressed in
CD11b+microglial cells in the ischemic striatum and CD11b+ cell accu-
mulation was reduced in TLR4-KO mice [64]. In ischemic brains, TLR2
expression was induced in lesion-associated microglia and TLR2-
deficient mice had decreased brain injury after focal cerebral ischemia
[97]. Systemically administered TLR ligands induce tolerance to subse-
quent ischemic injury and it has been proposed that stimulation of
TLRs prior to ischemia reprograms TLR signalingwhich leads to reduced
expression of pro-inflammatory molecules and enhanced expression of
anti-inflammatory mediators [108]. Investigation of stroke patients
demonstrated that upregulated expression of TLR4 in monocyte sub-
populations correlates with severity of acute cerebral infarction [160,
172]. TLR2 and TLR4 expression on monocytes were independently as-
sociated to poor outcome and correlated with higher serum levels of
IL1β, IL6, TNFα, and VCAM1 [10].
Findings in animal models and in humans suggest interactions be-
tween TLRs and complement. Microglial cells constitutively express the
receptors for complement cascade components: C1q and for cleavage
products of C3, thatmediate phagocytosis and stimulate cytokine produc-
tion bymicroglia. CR3 can regulate the signaling activity of TLR2 and TLR4
via an adaptor protein TIRAP, which acts as a sorting adaptor and facili-
tates the recruitment of the signaling adaptor MyD88 to either TLR2 or
TLR4. Microglia also respond to C1q with a pro-inflammatory activation
in CNS diseases with blood–brain barrier impairment [52].
1.2.2. Signaling via a TNF receptor family
TNF receptor family includes lymphotoxin (LT) receptor, Fas, CD40,
the low affinity nerve growth factor receptor, TRAIL receptors, RANK
Fig. 1. The TLR activation and MAPK signal transduction pathway A. TLRs in a response to different ligands initiate intracellular signaling via recruitment of the intracellular adaptor pro-
teins:MyD88 (myeloid differentiation factor 88); TIRAP (TIR-domain-containing adaptor protein), TRIF (TIR-domain-containing adaptor protein inducing IFN-β), and TRAM(TRIF-related
adaptor molecule). These adaptors can be differentially recruited to the TLR or and determine the specificity of signaling. B. MAPK family is composed of three modules serially activated
kinases: a MAPK kinase kinase (MAP3K), a MAPK kinase and ERK, JNK and p38 MAPK. Several substrates or indirect targets of each pathway are indicated. Abbreviations: ATF, activating
transcription factor; ASK, Apoptosis Signal-regulating Kinase; CBP, CREB binding protein; CREB, cAMP response element binding protein; Elk-1, Ets-like transcription factor; ERK, extra-
cellular signal-regulated kinase; Ets, transcription factor with v-ets domain (viral-E-twenty-six); GADD 153, growth arrest and DNA damage-inducible protein 153; iNOS, inducible nitric
oxide synthase; JNK, c-Jun amino-terminal kinase;MAPKAP-K2,MAP kinase-activated protein kinase 2;MEF,myocyte-enhancing factor;MEK,MAP/ERK kinase; MEKK, MEK kinase;MLK,
mixed-lineage protein kinase; MyD88, myeloid differentiation factor 88; NFAT4, Nuclear factor of activated T cells 4; NIK, NF-κB-inducing kinase; PAK, p21 activated kinase; TAK,
transforming growth factor-β-activated protein kinase; TAO, one thousand and one amino acids; TGF β, transforming growth factorβ; TLR, Toll-like receptors; TBP, TATA box binding pro-
teins; TNF, TumorNecrosis Factor; Tpl-2, Tumor progression locus 2 kinase; TRAF, TNF receptor associated factor; TRAM, TRIF-related adaptormolecule; TRIF, Toll/IL-1R domain-containing
adaptor-inducing IFN-beta.
341B. Kaminska et al. / Biochimica et Biophysica Acta 1862 (2016) 339–351and death or decoy receptors. TNF-α acts through two receptors: TNFR1
and TNFR2. TNFR1 contains a death domain (DD) in the cytoplasmic tail
that is not present in TNFR2. Activation of TNFR1 leads to the recruitment
of the adaptor protein TRADD (TNFR-associated DD), which can further
recruit receptor-interacting protein kinase 1 (RIP1), TNFR-associated fac-
tors (TRAFs) and Fas-associated death domain (FADD) [29].
The downstream signaling pathways diverge: association of FADD
with pro-caspase-8 leads to apoptosis, whereas association of TRAF-2
with the cytoplasmic inhibitor of apoptosis protein signals survival by
transcriptional activation of NF-κB and cFos/cJun. TRADD can also inter-
actwith the TLR4 complex after lipopolysaccharide (LPS) stimulation. In
TRADD deficient mice, TNFα induced apoptosis and TNFα-stimulated
NF-κB, JNK, and ERK activation was defective. TRADD-deficient macro-
phages show impaired cytokine production in response to LPS and
poly (I:C) in vitro. TRAF6 is a common mediator of the signals from dif-
ferent receptors, including the TNF receptors, IL-1R/TLR superfamily,
TGFβR, IL-17R and IL-25R, and the NOD-like pattern recognition recep-
tors [29,105]. The molecular switches and changes in the expression of
pathway components contribute to the multi-faceted roles of TNF-α
in stroke progression and rehabilitation.
Mice lacking TNF-α receptors exhibited enhanced neuronal damage
after kainate-induced seizures and focal cerebral ischemia [14], ortraumatic injury [146]. These data were corroborated by observations
of the increased infarction in TNFR1 (TNF-p55 receptor, TNF-p55R)-
KO mice [92]. Further studies demonstrated that the TNFR1, but not
TNFR2-KO, mice have significant reduction in JNK activation, reduced
microglial activation and blood–brain barrier breakdown which result-
ed in a smaller cortical andwhitematter injury after LPS-sensitized hyp-
oxic–ischemic injury in the immature brain [163].1.2.3. IκB kinase (IKK) complex in neuroinflammation
The pro-inflammatory cytokines, TLRs and other stress-like stimuli
activate NF-κB via the IκB kinase (IKK) complex, which contains kinases
IKKα, IKKβ and the regulatory subunit IKKγ/NEMO (NF-κB essential
modulator) [57]. Canonical signaling strictly depends on IKKγ, while
the catalytic subunits seem to be more redundant. IKKγ forms a func-
tional IKK complex with IKKα in response to IL-1β, but TNFα requires
IKKβ to form a signaling unit [51,144]. The non-canonical pathway is ac-
tivated by a narrow group of stimuli, such as lymphotoxin-α/β, BAFF or
CD40L, which trigger posttranslational stabilization of NF-κB interacting
kinase (NIK). The substrate spectrum of the IKK complex is not restrict-
ed to IκBs, but includes other proteins such as RelA and p53. Therefore,
the IKK complex besides its role as a signaling hub for NF-κB activation
342 B. Kaminska et al. / Biochimica et Biophysica Acta 1862 (2016) 339–351is also a platform for crosstalk between NF-κB activating pathways and
other physiological processes [57].
Deficiency of IKKβ in myeloid cells resulting from the LysM-Cre-Lox
knock out of the ikbkb gene in the myeloid cell lineage (LysM-Cre/
Ikkbeta mice) reduced neuronal cell death after kainate (KA)-induced
seizures which was associated with decreased KA-induced microglia
and astrocyte activation, and reduced expression of tnf-α and il-1β
[24]. Deficiency of IKKβ in myeloid cells in APP-transgenic (TgCRND8)
mice reduced inflammatory activation and Aβ accumulation in the
brain which was associated with reduction of cognitive deficits and
protection of synaptic proteins. IKKβ deficiency enhanced microglial
recruitment and facilitated Aβ internalization [104].
1.3. A MAP kinase cascade—a hub for inflammatory signaling in microglia
TLRs, receptors of TNFα, IL-1β and many other cytokines employ a
common signaling hub—MAP kinases—to transduce extracellular sig-
nals to the nucleus. Three major groups of distinctly regulated MAPK
cascades leading to altered gene expression: ERK1/2, JNK, and p38
MAP kinase are known in humans. ERK1/2 is activated by MKK1 and
MKK2, JNK by MKK4 and MKK7, and p38 MAP kinase by MKK3,
MKK4, and MKK6, respectively (Fig. 1). Upon activation of the MAP ki-
nases, transcription factors present in the cytoplasm or nucleus are
phosphorylated and activated, which results in transcription of target
genes. The multiple interactions between the different MAP kinase
cascades serve to integrate the responses and activate specific sets of
genes [75]. TAK1, which belongs to the family of mitogen-activated
protein kinase kinase kinases (MAP3Ks), is activated by cytokines
such as TNF-α, TGF-β as well as by LPS, and is upstream of
p38MAPKK, JNK and NF-κB in various cells. Recent advances in genetic
targeting of microglia enable to address specifically questions of
signal transduction in microglia activation [169]. Conditional deletion
of TAK1 (transforming growth factor (TGF)-β-activated kinase 1/
mitogen-associated protein kinase kinase kinase, MAP3K) in microglia
during autoimmune inflammation reduced the NF-κB, JNK and ERK1/2
activation, lessened CNS inflammation, and diminished axonal and my-
elin damage suppressing a disease [48]
The p38 MAPK family consists of four major isoforms encoded by
p38α (MAPK14), p38β (MAPK11), p38γ (MAPK12), and p38δ (MAPK13)
genes [3]. The expression of p38 MAPK isoforms differs: p38α was
expressed predominantly in monocytes, whereas p38δ expression was
low; in macrophages p38α and p38δ were abundant. Studies of knock-
inmice (the drug-resistant, p38αT106Mmice) demonstrated that inhibi-
tion of the p38α isoform in vivo is sufficient for suppression of increased
pro-inflammatory cytokine production in macrophages after a systemic
LPS challenge. Deletion of p38α (p38αΔM) only in the myeloid lineage
cells protected mice from the lethal effects of LPS or cecal ligation and
puncture induced sepsis [73]. The p38αMAPK inhibitor (069A) reduced
IL-1β and TNFα production induced by TLR agonists or Aβ in the BV-2
microglial cells and primary microglial cultures. Microglia from p38α-
KO mice showed the reduced cytokine production in response to LPS
and oral administration of the inhibitor blocked the increase of IL-1β in
the cerebral cortex of mice injected with LPS [4]. p38βMAPK deficiency
did not impair the pro-inflammatory cytokine production and neurotox-
icity after administration of LPS by intraperitoneal or intracerebroventric-
ular injection [170].
Major effects of p38 MAPK on the synthesis of inflammation media-
tors depend on MAPK-activated protein kinase 2 (MK2). The nuclear
MK2 facilitates translocation to the cytoplasm and phosphorylation of
tristetraprolin (TTP). TTP regulates mRNA turnover by binding to
adenine/uridine-rich element (ARE)-dependent and recruiting mRNA-
degrading enzymes which reduces a stability of mRNA [12]. The p38
pathway has been implicated in the regulation of mRNA stability of cy-
clooxygenase 2, tnf-α, il-3, il-6, il-8, cmp-1α, granulocyte-macrophage
colony-stimulating factor (GM-CSF), vascular endothelial growth factor,
urokinase-type plasminogen activator, and inos genes. MK2-KO micewere resistant to the LPS injury and did not induce TNFα or NO produc-
tion [91]. The expression of p38α and MK2 in microglia is several fold
higher than in neurons or astrocytes, and MK2 expression is further
increased in LPS and interferon γ-stimulated microglial cells. Elevat-
ed activation and expression of MK2 correlated with Aβ deposition,
microglial activation, in double-mutant APPswe/PSEN1.M146V
mice ([26]. Cultured microglia from MK2-KO mice had reduced ex-
pression of tnfα, ccl3, kc (mouse chemokine with highest sequence
identity to human GROs and interleukin-8) when challenged with
LPS and IFNγ or Aβ1–42 [26]. Increased expression and phosphoryla-
tion of MK2 in microglia/macrophages, neurons and astrocytes was
detected after spinal cord injury. MK2-KO mice showed better loco-
motor recovery, reduced neuron and myelin loss, and increased
sparing of serotonergic fibers in the injury site. This was associated
with the reduced expression of pro-inflammatory cytokines and pro-
tein nitrosylation [44]. Studies of immortalized bone marrowmacro-
phages from MK2-KO mice demonstrated that activation of the p38
MAPK/MK2 pathway is critical for imidazoquinoline S28463- (TLR7
ligand) and CpG DNA (TLR9 ligand)-induced cytokine and chemo-
kine production [158]. The myeloid-specific TTP deficiency resulted
in an early-onset, severe inflammatory phenotype, myeloid hyper-
plasia and autoimmunity [130].
MAPK are also involved in the regulation of the protein translation.
ERK and p38 MAPK phosphorylate MAPK signal-integrating kinase
1—Mnk1, which phosphorylates an eukaryotic initiation factor 4E
(eIF4E), crucial for initiation of protein synthesis [167]. Stimulation of
primary microglial cultures with fibronectin resulted in the activation
of the translational factor eIF4E via MEK-ERK-MNK1-dependent man-
ner. AnMNK1 inhibitor attenuated the increase of P2X (4)R inmicroglia
under inflammatory or neurodegenerative conditions [159].
JNKs regulate various physiological processes such as brain develop-
ment, repair, and memory formation but are potent effectors of neuroin-
flammation and neuronal death [56,161]. LPS, TNF-α and thrombin
induced a robust activation of JNKs in primary microglial cultures. Inhibi-
tion of JNKs with an inhibitor SP600125 reduced the LPS-induced meta-
bolic activity and the AP-1 inducible genes such as cyclooxygenase-2
(cox-2), tnf-α, mcp-1 and il-6. Inhibition of ERK1/2 and p38 α affected
LPS-induced cell enlargement [161]. Ciclosporin A or tacrolimus (FK506),
potent immunosuppressants and neuroprotectants inhibited ERK, p38
MAPK and JNKs activation in primary microglial cultures stimulated
with LPS. The treatment blocked many microglial functions: amoeboid
transformation, migration, cytokine gene expression (il-1β, il-6, tnfα)
andNOproduction [177]. Themechanismof inhibitory effects of immuno-
suppressants on phosphorylation of ERK, p38, and JNKs is unknown. The
inhibition does not fully rely on inhibition of calcineurin activity as both
drugs act at doses higher than required for calcineurin inhibition in glial
cells. FK506 is more effective, therefore, the inhibition of FK506-binding
proteins (FKBP) and downstream signaling molecules is likely.
Termination of MAPK signal transduction is carried out by dual-
specificity phosphatases (DUSP/MKP), dephosphorylate the regulatory
threonine and tyrosine residues on MAPKs [138]. DUSP3 is expressed
in human and mouse monocytes and macrophages and its deficiency
in mice led to tolerance to LPS-induced septic and cecal ligation and
puncture shock. Resistance to LPS was macrophage-dependent and as-
sociated with reduced TNFα production, impaired ERK1/2 activation
and increase of M2-like macrophages in Dusp3-KO mice [142].
MKP-1 (MAPK phosphatase-1), which preferentially dephosphory-
lates p38MAPK and JNK, is present in the nucleus. Mkp-1−/− peritoneal
macrophages exhibited prolonged p38 and JNK activation aswell as en-
hanced TNF-α and IL-6 production upon LPS challenge [179].MKP-1 de-
letion exacerbated stroke outcome in a MCAo model and consistently
the MKP-1 pharmacological inhibitor worsened stroke outcome of
wild type mice. MKP-1 deletion increased microglial JNK and p38
MAPK activation, IL-6 and TNF-α production, and apoptotic responses
after MCAo [104]. Several compounds with an anti-inflammatory activ-
ity such as endocannabinoid anandamide [33] or JWH015 (a CBR type II
Table 1
Components do JAK/STAT signaling.
Ligand Kinase STAT protein
IFNα/β TYK2, JAK1 STAT1, STAT2
IFNγ JAK1, JAK2 STAT1
IL6, IL11, OSM, LIF, CNTF JAK1 (JAK2) STAT3, STAT1
IL12, IL23 JAK2, TYK2 STAT4
EPO, GH, PRL, TPO JAK2 STAT5
IL3, IL5, GM-CSF JAK2 STAT5
IL2, IL7, IL9, IL15 JAK1, JAK3 STAT5
IL4, IL13 JAK1, JAK3 STAT6
EGF, FGF, HGF, PDGF JAK1, JAK2 STAT1, STAT3, STAT5
Abbreviations: CNTF, ciliary neurotrophic factor; IFN, interferon; IL, interleukin; EGF,
epidermal growth factor; EPO, erythropoietin; FGF, fibroblast growth factor; GH, growth
hormone; GM-CSF, granulocyte macrophage colony stimulating factor; HGF, hepatocyte
growth factor; LIF, leukemia inhibitory factor; OSM, oncostatin M; PDGF, platelet derived
growth factor; PRL, prolactin; TPO, thrombopoietin.
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microglial cells, reducing p-ERK1/2 level and cell migration in LPS-
stimulated primary microglial cultures [134]. Dexamethasone (Dex)
had the inhibitory effect on the mcp-1 mRNA and protein expression,
and suppressed ROS and NO release, migration and inflammatory re-
sponses of activated microglial cells in MKP-1 dependent manner
[185]. Overexpression of MKP-1 or inhibition of JNK and p38 MAPKs
with specific inhibitors down-regulated the expression of nox-2 and
inos in activated BV-2 cells in MKP-1 dependent manner [62].
The expression of CD45, a membrane-bound protein-tyrosine phos-
phatase (PTP) was found elevated in microglia in AD brain compared
with controls. Stimulation of microglial CD45 by anti-CD45 antibody
inhibited p44/42 MAPK and production of NO and TNFα, suggesting
that CD45 is a negative regulator of microglial activation. Cultured mi-
croglia from CD45-deficient mice were hyper-responsive to Aβ and
when crossed with a transgenic mouse model of AD (APPswe mice)
demonstrated markedly increased production of TNF-α compared
with CD45KO/APPswe mice [152].
Increased activities of MAPK, in particular p38MAPK, and their mul-
tifaceted involvement in the regulation of the inflammation mediator
synthesis, make them potential targets for anti-inflammatory therapeu-
tics. MAPK inhibitors, capable of reducing both the synthesis of pro-
inflammatory cytokines and their signaling, emerge as attractive com-
pounds blocking neuroinflammation resulting in many ongoing clinical
trials [2].
1.4. Cytokine signaling via JAK/STAT in microglia activation
Interferons (IFNs) are important signal transduction mediators in
the innate immune system influencing viral infections, inflammation,
and immune surveillance [81]. IFN-α and IFN-β are the predominant
Type I IFNs in the CNS, mostly produced in microglia and astrocytes.
The signaling pathway for both IFN-α and IFN-β involves IFNAR, a com-
mon cell surface receptor. IFNAR associates with STAT1 and STAT2, to-
gether with IFN regulatory factor (IRF)9 form a complex that binds to
IFN-stimulated response element (ISRE) in promoters of many genes.
It stimulates a type I IFN-dependent transcription of IRF7, described as
a master regulator of type I IFN signaling. IFN-γ is a type II interferon
which triggers antiviral and adaptive immune responses through a
Jak-STAT signaling pathway [122].
Members of the JAK family include: Jak1, Jak2, Jak3, and Tyk2.
Functional and physical association of Jak1 with receptors for the type
I (IFN-α/β), type II (IFN-γ) interferons, IL-2, and IL-6 have been report-
ed. Biochemical studies and analyses of Jak2-KO tissues confirmed an
important role of Jak2 in the response to receptors binding the single-
chain peptides, IL-3, 5 and GM-CSF cytokine families, as well as the
IFN-γ receptor. Leukocyte-specific Jak3 associateswith the IL-2 receptor
γ-chain, which serves as a component for the receptors of cytokines
(IL-4, -7, -9, -15, -21). Tyk2 associates with receptors for IFN type I,
IL-6, IL-10 and IL-12/23 cytokine families [139] Table 1. summarizes
various elements of JAK/STAT signaling employed by cytokines and
growth factors.
Cytokine-derived immune signaling is strictly regulated with re-
spect to both magnitude and duration. Inhibitory molecules including
the suppressors of cytokine signaling (SOCS1–7), cytokine-induced
STAT inhibitor (CIS) and protein inhibitor of activated STAT (PIAS)
form the negative feedback regulation of JAK-STAT signaling [46,176].
Those inhibitory proteins inactivate JAKs and block the access of
STATs to receptor binding sites. SOCS inactivate JAKs, CIS binds to
STAT on the activated receptor and PIAS associates with tyrosine-
phosphorylated STAT dimers. The myeloid-specific SOCS3-deficient
mice were more vulnerable to myelin oligodendrocyte glycoprotein
(MOG)-induced EAE (experimental autoimmune encephalomyelitis),
with a severe, non-resolving form of disease, showed enhanced infiltra-
tion of inflammatory cells and demyelination in the cerebellum.
Myeloid-specific SOCS3-deficient mice had enhanced STAT3 signaling,upregulated expression of inflammation mediators (inos, il-1β, il-
12p40, il-23p19, il-6, ccl2, cxcl10, and ifr5) and an immune response
dominated by Th1 and Th17 cells. Adoptive transfer ofM2macrophages
into myeloid SOCS3-deficient mice delayed onset and reduced severity
of disease [128].
JAC2was activated by LPS and via Stat5 regulated LPS-induced IL-6 ex-
pression [82]. Resveratrol had anti-inflammatory effects in LPS-stimulated
murine N13 microglial cells through up-regulating socs-1 expression, as
this effect was lost in the presence of socs-1 siRNA [32]. Resveratrol treat-
ment also prevented the pro-inflammatory effect of LPS or fibrillar Aβ on
BV-2 andRAW264.7 cells by inhibiting activation of STAT1 andSTAT3, IκB
phosphorylation, IL-1β, TNF-α and IL-6 secretion [17].
Protein tyrosine phosphatases such as Src homology 2 (SH2)
domain-containing phosphatases (SHP)-1 and SHP-2 are other regula-
tors of cytokine signaling. SHP-1 deficientmice (spontaneousmutations
at the “motheaten” locus) had weaker microglial activation and were
less susceptible to focal cerebral ischemia induced by MCAo [6]. LPS
stimulated microglia from those mice produced more NO, IL-1β and
TNF-α [178].2. Transcriptional programs underlying microglia activation
The initiation of inflammation requires global activation of gene ex-
pression, postranscriptional regulation, epigenetic modifications and
changes in chromatin structure. Analyses of many transcriptomics
data derived fromhuman andmurinemicroglia show thatmicroglia ex-
press a different set of genes than peripheral macrophages [15,38,55].
Microglial functions are regulated in a signal-specific manner, allowing
these cells to develop specific functional programs [7,15,34]. The in-
flammatory activation of cultured microglia (stimulated with LPS) in-
duced transcriptional responses that are similar to inflammatory
responses of microglia under pathophysiological conditions in vivo [].
Global gene expression profiling on the ischemic cortex/sham operated
cortex and Gene Ontology functional analysis revealed overrepresenta-
tion of functions such as responses to wounding and external stimuli,
inflammatory, immune system and defense response, response to
stress, cell death [177]. The same categories of genes were overrepre-
sented in LPS-stimulatedmicroglia. The analysis of predominant signal-
ing pathways in LPS-stimulatedmicroglia revealed NF-κB and JAK/STAT
pathways on the top of the ranking list. Transcriptomic analysis of mi-
croglia from the corpus callosum during demyelination/remyelination
in themouse cuprizonemodel, showed the presence of amicroglia phe-
notype that supports early remyelination and continue throughout the
remyelination process. The changes indicated microglia involvement
in the phagocytosis of myelin debris and apoptotic cells during
demyelination (Lrp1, Calr, Cd14 and Itgb2, Itgam, and Lgals3). Microglial
expression of cytokines and chemokines supporting recruitment of en-
dogenous oligodendrocyte precursors to the lesions (e.g., Cxcl10, Cxcl13
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and Mmp14) was detected [121].
Transcriptome analysis of microglial cultures stimulated to induce
M1 (LPS stimulation) or M2-like activation (exposure to glioma-
conditioned medium, GCM) uncovered two patterns of gene expres-
sion. Many inflammation- and immune system-related genes and sig-
nalling pathways characteristic for M1 inflammatory activation of
microglia failed to be induced in glioma-exposed microglia. Glioma-
induced activation was associated with induction of genes coding for
transcription regulators: ID (inhibitor of DNA binding) 1/3, c-Myc,
Smad7, markers of the M2 phenotype: Arg1, MT1-MMP, CXCL14, IGF-
1, and numerous cytokines/chemokines implicated in immune cell traf-
ficking [34]. Most of the genes upregulated by GCM were down-
regulated in the inflammatory microglia. Gene expression patterns for
the BV-2 microglial cell line stimulated with viral dsRNA Poly (I:C) or
LPS (as evaluated by RNA-seq) were similar as gene patterns detected
in LPS-stimulated ratmicroglia cultures. Transcription factormotif anal-
ysis (−950 to +50 bp of the 5′ upstream promoters) demonstrated
that the DNA sequences for NF-κB, IRF1, and STAT1 were significantly
enriched in TLR agonists-stimulated microglia [28].
Interpretation of microglial transcriptome-based studies have to be
considered with a caution. Comparison of the transcriptomes of FACS-
sorted CX3CR1-GFP labeled microglia isolated from the brainstem of
adult mice to laser capture microdissection (LCM) demonstrated major-
ity of shared transcripts but also transcripts unique to FACS-isolated and
LCM-captured microglia. A half of LCM-isolated microglial transcripts
represented genes characteristic for neurons and glia, and these tran-
scripts were not translated into protein. Levels of oligodendrocyte and
neuronal transcripts were increased inmicroglia following the induction
of EAE, while only the myelin basic protein transcript level increased in
microglia after traumatic brain injury [143]. A very useful resource in
studying microglial transcriptome is a recently published Glia Open Ac-
cess Database (GOAD) (www.goad.education) which contains a collec-
tion of published and unpublished transcriptomic data, including data
sets from isolated microglia, astrocytes and oligodendrocytes under
physiological and pathological conditions [59]
Convergence of neuroinflammation-related signaling pathways on
specific transcription factors discussed above and transcription factor
motif analysis of co-regulated genes in various microglial data sets
established transcription factors NF-κB/Rel, AP-1, IRFs, and STATs as
master regulators of inflammatory gene expression in microglia under
neuroinflammatory conditions.
2.1. The NF-κB transcription factor
The NF-kappaB (NF-κB) protein family consists of distinct members,
including NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB,
and c-Rel, that form homo- and heterodimers. In resting cells, NF-κB di-
mers are sequestered in the cytoplasm through interaction with IκB
proteins (IκBα, IκBβ and IκBε) or the precursor proteins p100 and
p105. Induction of NF-κB depends on the phosphorylation of IκBs on
serine residues resulting in IκBsubiquitination by theE3 ubiquitin ligase
and degradation by the proteasome [53]. Activation of NF-κB inmicrog-
lia, through the increase of IKKβ expression, induced a classical M1 pro-
inflammatory phenotype [37] The early phase of inflammatory re-
sponse is predominantly associated with the nuclear accumulation of
p50/RelA dimer, known to activate transcription of proinflammatory
genes coding for cytokines TNFα, IL-1β and IL-6, iNOS, and proteolytic
enzymes in microglia. NF-κB precursors are processed by the protea-
some to produce the mature transcription factors p50 and p52 [101].
Both TLR-dependent and -independent pathways engage the IKK com-
plex and related kinases TBK-1 and IKKε. Activation of theNF-κB and IRF
transcription factor pathways are essential early steps of immune acti-
vation [77].
There is the extensive literature on the involvement of NF-κB in reg-
ulating cytokine cascades during neurodegeneration and differentcontribution of distinct NF-κB subunits to inflammatory responses in
glial cells, neuronal cell death or survival [111,124,133]. Agents that in-
hibit NF-κB usually suppress LPS-induced Cox-2 expression, but the role
of microglial NF-κB in neuronal injury is complicated by the fact that ac-
tivated microglia produce neurotrophic factors such as NGF, bFGF, and
modulation of NF-κB have been shown to prevent neuronal death in
various experimental models of neurodegenerative disorders [111].
There are a few studies directly assessing a role of NF-κB in
microglial functions. LPS, IL1β and TNF-α activated NF-κB and stimulat-
ed RANTES (regulated upon activation of normal T cell expressed and
secreted) production in a NF-κB dependent manner in human fetal
brain microglia [61]. The expression of Jmdj3, a transcription factor
and histone demethylase that controls the inflammatory responses, is
regulated by NF-κB in LPS-stimulated primary rat microglial cultures
similarly as in peripheral macrophages [127].
2.2. The AP-1 transcription complex
The AP-1 (activator protein 1) complex, composed of Fos (c-Fos,
Fos, Fra1/2) and Jun (c-Jun, JunB, JunD) proteins, binds to regulatory
DNA sequences (AP-1 and ATF/CRE-like consensus motifs) and acti-
vates the basal transcription machinery. While c-Jun is mostly acti-
vated by phosphorylation, other components of the AP-1 complex
are transcriptionally activated. ETS-domain ternary complex factors
(TCFs), including Elk-1 and SAP-1 are phosphorylated and activated
by ERK, JNK and p38, or ERK and p38, respectively, which leads to en-
hanced transcription of the c-fos gene. Up-regulation of c-jun and c-
fos followed by formation of the AP-1 complex is required to target
promoter elements of many genes. Phosphorylation of c-Jun and
ATF-2 proteins by JNK and p38 MAPK leads to increased transcrip-
tional activity of the AP-1 transcription factor [54,70]. The AP-1 tar-
get genes include genes coding for many cytokines, chemokines
and their receptors, metalloproteinases and their inhibitors, and
are upregulated during neuroinflammation [54] but their regulation
by AP-1 complex in microglial cells has not been evaluated. Alterna-
tive splicing of Fosb mRNA generates Fosb and ΔFosb, encoding full-
length FosB and ΔFosB proteins, respectively. Microglia express
equivalent levels of Fosb and ΔFosb mRNAs to hippocampal neurons
and six microglial genes were identified as dependent on FosB, in-
cluding c5ar1 and c5ar2, that encode receptors for complement
C5a. Microglia isolated from Fosb-KO had lower chemotactic respon-
siveness toward C5a. Microglial activation after kainate-induced
excitotoxicity was significantly diminished in Fosb-KO hippocam-
pus, levels of il6 and tnf mRNAs were reduced. The results suggest
that FosB contributes to a neuroinflammatory response in the hippo-
campus through regulation of microglial C5ar1 and C5ar2 expression
[119].
Recent studies using mice lacking JunB in myeloid cells showed that
JunB is a modulator of both classical and alternative macrophage
activation. JunB was required for expression of il1b and several M1
inflammation-related genes in macrophages treated with LPS and
other immunostimulatorymolecules. Furthermore, JunBmodulated ex-
pression of canonical markers of M2 activation in macrophages treated
with IL-4 [36]. Myeloid-restricted deletion of Junb reduced type 1 im-
mune activation (an experimental cerebral malaria model), which was
associated with reduced cerebral pathology and improved survival dur-
ing infection. Myeloid JunB deficiency also compromised M2 activation
(a hookworm infection model) leading to diminished cytokine produc-
tion, eosinophil recruitment and increased parasite load. These results
demonstrate that JunB in myeloid cells shapes host responses and out-
comes during type 1 and type 2 infections [36].
2.3. Signal transducers and activators of transcription
STATs (Signal Transducers and Activators of Transcription) are a
family of transcription factors (STAT 1, 2, 3, 4, 5a, 5b, 6) that are
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tors. Each STAT protein has a DNA binding domain, a src-homology
2 (SH2) domain necessary for homo- or heterodimerization and a
conserved tyrosine residue 705 phosphorylated by tyrosine kinases.
Phosphorylated STAT dimers translocate to the nucleus and bind to a
consensus DNA element upstream of regulated genes. Stat5a and
Stat5b proteins alone are weak activators of transcription, and they
act predominantly by cooperating and interacting with other pro-
teins. The activation of individual STATs is temporary and usually
lasts from a fewminutes to several hours under normal physiological
conditions [99,123].
Hundreds of genes have been identified by knockout and biochemi-
cal studies as potential Stat3 targets, but only a small fraction has been
proved to be direct Stat3 targets in various cells. A meta-analysis of 29
ChIP-seq data sets of STATs DNA binding in macrophages, B and T lym-
phocytes, embryonic fibroblasts, embryonic cells and liver cells revealed
that most of the classical STAT-binding sites were located near genes
with cell-specific expression, and STAT binding pattern is unique in
each cell type [74]. Studies of Stat1 and Stat3 binding sites in LPS-
activated primary microglial cultures, using chromatin immunoprecipi-
tation and promoter array hybridization (ChIP-chip), revealed novel
Stat-target genes including jmjd3, ccl5, ezr, ifih1, irf7, uba7, and pim1 [].
Functional manipulations of Stat signaling (silencing or overexpression
of Stats) were performed on BV2 cells. While knockdown of individual
Stat had little effect on the expression of tested genes in BV2 microglial
cells, knockdown of both Stat1 and Stat3 inhibited the expression of
jmjd3 andother inflammatory genes. In BV2 cells overexpression of con-
stitutively active Stat1 and Stat3 was capable of recapitulating global
gene expression profiles and cytokine production (except IL-10). Tran-
scriptional regulation of Jmjd3, a transcription factor and histone
demethylase [30], by Stat1 and Stat3 is a novel mechanism of transcrip-
tional control of inflammatory gene expression in microglia [127].
2.4. Interferon responsive factors
Interferon regulatory factors (IRFs) comprise a family of transcrip-
tion factors that recognize DNA similar in sequence to the IFN-
stimulated response element (ISRE) and modulate different sets of
genes, depending on the cell type and/or the nature of cellular stimuli.
Four IRFs: IRF1, IRF3, IRF5, and IRF7 have been implicated as positive
regulators of type I IFN elicited gene transcription [66,184]. Gene-
targeting study demonstrated that in haematopoietic cells from Irf5-
deficient mice, the induction of pro-inflammatory cytokines il-6, il-12
and tnf-α by various TLR ligands was impaired, whereas induction by
interferon-α unimpaired [151].
Functions of IRFs in microglial cells are still poorly known. In cul-
tured microglial cells, signaling through the prostaglandin-E2 (PGE2)
EP4 receptor attenuated levels of Aβ-induced inflammatory factors
and potentiated Aβ phagocytosis. Microarray analysis demonstrated
that EP4 stimulation had an opposite effect on Aβ-driven gene expres-
sion changes in microglia. The genes modulated by EP4 stimulation
were enriched in targets of IRF1, IRF7, and NF-κB transcription factors
[166]. The expression of IRF7 was increased in LPS treated microglia
in vitro and in vivo. Knockdown of IRF7 using siRNA suppressed the ex-
pression of LPS-induced genes and reduced phosphorylation of STAT1
[153]. Also IRF8 is strongly implicated in initiation of a reactive pheno-
type of microglia [114]. Loss of IRF8 did not affect development and col-
onization of CNS by microglia but IRF8-deficient microglia had less
elaborated processes with reduced expression of microglial marker
IBA1, reduced phagocytic capacity and were less proliferative in
mixed glial cultures than wild-type microglia. Exogenous macrophage
colony stimulating factor (CSF1) restored defective proliferation of
IRF8-deficient microglia in mixed glial cultures and granulocyte-
macrophage colony stimulating factor (CSF2) intensifiedmicroglial pro-
liferation. Cultured IRF8-deficient microglia had reduced Il12B mRNA
levels in response to IFNγ and LPS. Defective scavenging activity ofIRF8-deficient microglia was confirmed in the cuprizone-induced de-
myelination model in mice [60]. IRF8 was upregulated in the spinal
cord microglia following a peripheral nerve injury. Its overexpression
in cultured microglia promoted the inflammatory gene expression
(il1b,tlr2, p2rx4, p2rx12, cx3cr1, ctss) and deficiency prevented these
gene expression in the spinal cord. Furthermore, IRF8-deficient mice
were resistant to neuropathic pain, and transfer IRF8-overexpressing
microglia to a spine of normal mice produced pain [109]. IRF8 has
been implicated in regulatingmicroglialmigration. Chemotaxis induced
by ATP and a complement component C5a was suppressed in microglia
lacking IRF8 (Irf8-KO). Consistently, phosphorylation of Akt (a kinase
participating in ATP-induced chemotaxis) and the expression of
motility-related genes such p2ry12p,p2rx4 and adora3 (coding for
purinergic and adenosine receptors, respectively) was abolished in
Irf8-KOmicroglia.Moreover, Irf8-KOmicroglia showed reduced expres-
sion of antpd1 coding for an ectonucleotidase ENTPdase1, which hydro-
lyzes ATP to ADP and adenosine monophosphate and is predominantly
expressed in microglia [110].
3. Epigenetic control of microglia activation
3.1. Epigenetic mechanisms control transcriptional responses
Epigenetic mechanisms are mediated by non-coding RNA, post-
translational modifications (mainly methylation, acetylation, and phos-
phorylation) of histones and other chromatin proteins that bind DNA,
and bymethylation (5-methylcytosine [5mC]) and hydroxymethylation
(5-hydroxymethylcytosine [5hmC]) of DNA [11]. Global changes of DNA
methylation were detected in Alzheimer disease. Global levels of 5mC
and 5hmC positively correlated with amyloid β, tau, and ubiquitin
loads. Immunoreactivity for 5mC and 5hmCwere significantly increased
in affected structures of AD patients, mostly in neurons [25].
3.2. A role of miRNAs in microglia activation
MicroRNAs (miRNAs), a family of non-coding RNAs ~22 nucleotides
in length, are post-transcriptional regulators of gene expression.
miRNAs silence target genes by binding to their 3′-untranslated region
(3′-UTR) ofmessenger RNA (mRNA) [49]. Over the past decade, a grow-
ing body of evidence has revealed the important role of miRNAs in
inflammation and immunity [8,102], including their capability of regu-
lating the activation of macrophages [102]. However, only in the past
couple of years microglia have been a matter of study, and thus the rel-
evance of miRNAs on specifically microglial activation is still not fully
understood. Table 2 summarizes the current state-of-the-art on this
subject.
Cardoso et al. were the first to report the pro-inflammatory effect of
miR-155 in vitro [18]. LPS stimulation of N9 murine microglial cell line
and primary microglia cultures promoted the expression of miR-155.
The overexpression of miR-155 led to a decrease of SOCS-1, a negative
regulator of inflammation. miR-155 was shown to be responsible for
the production of pro-inflammatory mediators, as transfection of N9
cells with anti-miR-155 oligonucleotides lead to a decrease of IFNβ,
TNFα, IL-6, and INOS after incubationwith LPS. Furthermore, the inhibi-
tion of miR-155 decreased the LPS-stimulated microglia-mediated tox-
icity on primary cortical neurons, suggesting that miR-155 can be a
target for neuroprotection [18]. This notion was reinforced by observa-
tion of the miRNA expression profile of primary murine microglia cul-
tures after M1-polarization with LPS and M2a-polarization with IL-4.
Microglial activation towards the M1-phenotype was accompanied by
up-regulation of miR-155 and down-regulation of miR-689 and miR-
124.,miR-155 seemed to be the main miRNA driving this polarization.
On the other hand, M2a-polarization of microglia resulted in a higher
expression of miR-145 and miR-214, and lower expression of miR-711
[38].
Table 2
A summary of miRNAs effects in microglia.
miRNA Effect Potential mechanism Reference
miR-155 Pro-inflammatory Decrease of SOCS-1 [18]





Reduction of caspase 3
[117]
miR-203 Anti-inflammatory Decrease of MyD88 [173]
miR-21 Anti-apoptotic Decrease of FasL [180]






Reduction of CDC25A, CDK6
and cyclin D1
[183]
Abbreviations: CDC25A, cell division cycle 25A; CDK6, cyclin-dependent kinase 6; FasL, Fas
ligand; miRNAs, microRNAs; MyD88, myeloid differentiation factor 88; SIRT1, sirtuin 1;
SOCS-1, suppressor of cytokine signaling 1; TLR4, Toll-like receptor 4.
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sociated with the release of Fas ligand (FasL), which has a pro-
apoptotic effect in neurons, and the decrease of miR-21 mRNA expres-
sion [180]. Transfection of microglia with miR-21 mimics, and conse-
quent over-expression of miR-21, decreased both mRNA expression
and FasL protein level [180]. Neurons treated with conditioned media
(CM) from miR-21-transfected microglia subjected to OGD presented
reduced apoptosis, when compared to neurons treated with CM from
non-transfected cells [180]. In primary microglial cultures subjected to
OGD, miR-203 reduced MyD88-mediated inflammation. Additionally,
miR-203 mimics were protective in experimental stroke in mice, de-
creasing protein levels of the inflammatory cytokines IL-8 and TNFα,
whilst being able to reduce the expression of MyD88 and NF-κB in the
ischemic brain [173].
Earlier this year, Li et al. reported miR-204 as an inhibitor of SIRT1
expression. miR-204 upregulates pro-inflammatory markers, such as
iNOS and IL-1β, in N9 cells. Furthermore, the inhibition of miR-204
was able to restore the LPS-induced reduction of SIRT1, suggesting
that the pro-inflammatory effect of miR-204 can be partly due to a inhi-
bition of SIRT1, and that resveratrol can restore SIRT1 levels inmicroglia
and, thus, decrease microglia-driven inflammation [100]. In vitro, LPS-
stimulated and oxygen and glucose-deprived BV2 cells and primarymi-
croglia cultures showed a decrease in let-7c-5p expression. Treatment
of microglia with CM from neurons subjected to OGD produced similar
results. Over-expressing let-7c-5p in BV2 cells led to a decrease of both
LPS and OGD-induced inflammation. In addition, let-7c-5p reduced the
expression of caspase 3, by directly targeting its 3′-UTR [117]. Consider-
ing that miRNAs are important components of inflammation, NF-κB
pathway appears as an ideal target of miRNA regulation in microglia.
Consistent with this premise, the 3′-UTR of MyD88 mRNA contains
binding sites for miR-203 [173], and miR-181c targets the 3′-UTR of
TNF-α [181] and TLR4 [182] mRNAs.
The expression of miRNAs is controlled by promoters that in some
cases are regulated by NF-κB. OGD-activation increased TLR4 and NF-
κB/p65 protein expression in primary microglia cultures, which was
blocked by over-expressing miR-181c [182]. miR-181c-induced de-
crease in inflammatory markers was mediated by TLR4 suppression
[182].
Although there is a clear need for further research on this subject, an
application of miRNAs appears to be a promising strategy for the treat-
ment of diseases characterized by microglia-mediated toxicity. Recent
in vivo studies have addressed this growing potential. Ponomarev and
colleagues have recently shown that miR-124 regulates microglial acti-
vation, both in vitro and in vivo. miR-124 expression was elevated in ac-
tivated microglia. In macrophages, miR-124 was responsible for
inhibiting C/EBP-alpha directly and, subsequently, transcription factor
PU.1. In addition, over-expression of miR-124 induced phenotypicchanges in macrophages, displaying features like those of ramified
resting microglia, and shifted their polarization from the classical
M1 activation to the alternative M2 [126]. In vivo, treatment with
miR-124 reduced inflammation and ameliorated clinical symptoms
in diverse mouse models of EAE. Concomitantly, miR-124-treated
mice presented mostly CD11b+CD45lowresting microglia, as op-
posed to activated microglia in the sham group [126]. Zhao et al.
identified miR-424 as a regulator of microglia-mediated inflamma-
tion in ischemic stroke. The level of miR-424 decreased in plasma
of patients after ischemic stroke, and similar findings were reported
in mice following MCAo Pre- and post-treatment of mice with miR-
424 was protective and decreased microglial activation. Over-
expression of miRNA-424 attenuated the increase in the level of
Iba-1 and TNFα 8 h after MCAo, as well as decreasing cell-cycle acti-
vators CCND1, CDC25A and CDK6, which could be the mechanism re-
sponsible for the decrease of microglial activation [183]. These
results were reproduced in vitro in BV2 microglial cells, where miR-
424 mimics reduced the mRNA expression of TNFα and IL-1β after
1 h of OGD, and decreased cell-cycle activators expression [183].
miRNA let-7c-5pwas decreased in patientswith ischemic stroke and
in mice after MCAo [117] Over-expression of let-7c-5p was able to pro-
tect mice against ischemic injury. Moreover, it also reduced post-
ischemic inflammation, by significantly reducing the expression of il-6,
cox-2, tnf-α and inos mRNAs in the cortical penumbra, and decreasing
Iba1 staining in the ipsilateral cortex [117].
Taken together, these results suggest that targetingmiRNAs can be a
neuroprotective therapeutic approach worth considering in neurologi-
cal diseases characterized by microglial activation.3.3. Histone modifications
The balance of positive and negative histone marks at gene pro-
moters and distal regulatory elements regulates transcription rates.
Combinations of histone marks define chromatin states, which deter-
mine basal transcription rates, magnitude and kinetics of gene expres-
sion [69,156]. Epigenetic marks are typically more stable than the
rapidly modulated post-translational modifications of signaling pro-
teins and may persist after the original stimulus has resolved. Epige-
netics provides a mechanism for converting transient short-lived
signals into more persistent cellular responses lasting several hours or
days (or longer). Histones are subject to post-translational modifica-
tions that greatly influence gene expression, as they allow or deny ac-
cess of the transcriptional apparatus to DNA. These modifications
include methylation, acetylation, phosphorylation, ubiquitination,
amongst others [79,80].
Histone acetylation andmethylation are the most studied modifica-
tions of histone. The state of histone acetylation depends on histone
acetyltransferases (HATs) and histone deacetylases (HDACs), enzymes
responsible for acetylation and deacetylation, respectively. HATs, that
transfer an acetyl group from acetylCoA on lysine histone tails, have
shown distinctive functions in active genes and include pCAF, CBP,
p300, Tip60, MOF and GCN5 [165]. HDACs act through the removal of
the acetyl group from lysine residues on histones,whichpromotes chro-
matin condensation and thus makes DNA less accessible for transcrip-
tion factors, decreasing gene expression. Human HDACs are divided
into five main subtypes [78]. Class I (HDAC1, 2, 3 and 8) and class II
HDACs are Zn2 + −dependent deacetylases and share similar struc-
ture. The latter presents tissue-specific expression [107] and can be
subdivided into class IIa (HDAC4, 5, 7 and 9) and IIb (HDAC6 and
10). Class IV (HDAC11) shares characteristics of both class I and
class II HDACs [40]. Lastly, class III HDACs (Sirtuin1-7), unlike other
HDACs, have a NAD+-dependent activity, displaying distinctive
structure and function [120]. Several HDAC inhibitors (HDACi)
have been developed over the last years, with different HDAC inhibi-
tion selectivity [186].
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HDACs [125] working in equilibrium. Neurodegeneration, a state char-
acterized by death of neurons and neuroinflammation, is associated
with a loss of acetylation equilibrium [137], mainly due to a decrease
of HAT activity [135]With the aim to investigate the effect of increasing
acetylation, a number of studies have shown the beneficial activity of
HDAC inhibition in animal models of AD [85,129,148], HD [58,157],
and multiple sclerosis ([16,41] Particularly, a significant body of data
comes from models of acute CNS injury such as stroke [35,88,131,171,
175] and trauma [27,140,162]. Data are summarized in the Table 3.
These studies support the notion of HDACi as a valid treatment for
neurodegenerative disorders. Furthermore, someHDACi are already ap-
proved for human use in diseases such as epilepsy [42] and cancer [31,
87]. Recent published data showed improvements in adding valproate
to the standard post-insult stroke treatment in humans [96]. However,
due to the low number of patients included in the study, further clinical
trials with larger number of patients are needed to demonstrate the ef-
ficacy of valproate in stroke.
3.4. Microglia as a target of HDACi treatment in ischemic stroke
The acetylation level of histone H3 decreases in animal models of is-
chemic stroke [88,131]). HDAC expression was shown to be altered in
models of stroke both in vivo and in vitro [5]. Moreover, microglia can
be cellular targets of HDAC inhibition, and two studies demonstrated
an HDACi-induced protection against ischemic damage that depends
on anti-inflammatory effects on microglia [88,171]. However, little is
known about the effect of HDAC inhibition in stroke-induced microglia
inflammation.
Three different HDACi, valproic acid (VPA), sodium butyrate (SB)
and trichostatin A (TSA), reduced ischemic injury when administered
after pMCAO [88]. VPA and SB reduced the number of OX42-positive
cells in the ischemic corpus callosumboth 24 and48h after the ischemic
insult. These drugs decreased the activity of iNOS. The authors also re-
ported that VPA increased the number of caspase-3-positive microglia,
suggesting microglial apoptosis, which could explain, at least partially,
an anti-inflammatory effect of VPA. HDACi were able to block the de-
crease in the acetylation of histone H3 seen after MCAo, which supports
the notion that protectionwasmediated by an inhibition of HDAC activ-
ity. However, there is no data yet on the role of HDACi on histone mod-
ifications at the promoters of apoptotic genes in microglia. VPA, SB and
TSA induced apoptosis in primary rat microglial cultures. This effect oc-
curred at HDACi concentrations that increased histone H3 acetylation,
that suggests HDAC inhibition as a mode of action [20].
3.5. Effects of HDAC inhibition on microglia-induced inflammation
Treatment of microglia with HDACi was shown to amplify LPS-
induced inflammation in various cellular models [141]. Experiments
performed by our research group are in line with this finding
(unpublished data). In contrast, a treatment with HDACi, such as
scriptaid, SAHA, VPA [164], and pretreatment with TSA [147], led to a
decrease in inflammatory markers. The complex nature of HDACTable 3
Dualistic effect of HDAC inhibition in LPS-stimulated microglia.
HDAC inhibitor Cell type Treatment schedu
SB and TSA Rat primary microglia Pretreatment
SB
SB




TSA Human primary microglia Pretreatment
TSA Murine N9 cell line
Rat primary microglia
Simultaneous trea
TSA Murine N9 cell line Simultaneous trea
Scriptaid, SAHA, VPA Mouse primary microglia Posttreatment
Abbreviations: SAHA, suberoylanilide hydroxamic acid; SB, sodium butyrate; TSA, trichostatininhibition in microglia in vitro must be highlighted. Opposing effects of
the treatment of microglia with HDACi were reported by the same re-
search groups [20,150]. Chen et al. [20] described both a decrease and
increase in the LPS-induced inflammatory response of microglia, de-
pending on whether cells were pretreated with SB or TSA, or if they
were added concomitantly with LPS. Suuronen et al., [150] reported
similar findings, where TSA and SAHA enhanced the inflammatory ef-
fects of LPS when added at the same time. TSA induced the expression
of il-6 and inos mRNA and the secretion of IL-6, TNFα and NO. This po-
tentiating effect was blocked by NF-kB inhibitors [149,150]. However,
when microglia were pretreated with TSA before LPS stimulation, TSA
had an anti-inflammatory effect [150]
While Huuskonen et al. [63] reported that SB, either in pretreatment
or added at the same time to LPS, could potentiate LPS-induced inflam-
mation in N9 microglial cells, they also reported different effects in
transformed vs. non-transformed microglial cells, as pretreatment
with SB reduced LPS-induced inflammation in rat primary microglial
cultures. Simultaneous treatment of SB with LPS did not reduce inflam-
mation to the same extent, as only IL-6, but not TNFα or NO, decreased.
To understand the mechanisms underlying the dual effect of HDACi on
microglia activation when applied in diverse “temporal” windows de-
serves further investigation. Most important will be to understand if
in vitro findings can be reproduced in vivo, and whether the HDACi-
induced protection in stroke animal models, is because or in spite of
their effect on microglia.
The role of HDAC and effects of HDACi on the M1-M2 microglial po-
larization are still for themost part unknown, and have been amatter of
study only in the last couple of years. Singh et al. [141] reported that VPA
and SB treatment results in shifting pro-M1 and anti-M2 activation in
LPS-activated rat microglia, as both drugs increased tnfα and il-1β
mRNA levels and decreased il-10 gene expression. On the other hand,
TSA pretreatment could diminish not only LPS-induced inflammation
but also IL-4-induced expression of arginase-1 and Fizz1 mRNA, coding
for M2 phenotype markers [72], suggesting that pretreatment with
HDACi could induce deactivation of microglia and turn them into less
reactive cells, thus inducing microglial immunosuppression, and con-
tributing to the overall anti-inflammatory effects HDACi in vivo. Recent-
ly, Wang and colleagues reported [164] that Scriptaid decreased the
expression of M1-polarization markers (iNOS, CD16) and increased
those of M2 (CD206, IL-10) in a model of traumatic brain injury. With
such opposing and scarce data, it is premature to comment on the role
of HDACs in microglia activation, both in vitro and in vivo.
4. 5. NF-κB acetylation in the control of microglia activation
Acetylation of RelA on specific lysine residues (K122, 123, 218, 221,
and 310) is a dynamic process that differently affects the RelA interac-
tion with IκBα, the DNA-binding ability and specific transcriptional ac-
tivity of the protein [21,83]. The acetylation state of RelA, likewise that
of histones, is regulated by HATs and HDACs [50]. Members of class I
HDACs, HDAC1, HDAC2 and HDAC3 inhibited by vorinostat and
entinostat (MS-275), are responsible for the general deacetylation of









A; VPA, valproic acid.
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lectively deacetylates RelA at lysine 310 (K310) [94,174]. Recent studies
show that pro-apoptotic transcription induced by NF-κB p50/RelA in
acute brain ischemia [187,188] relies on the specific derangement of
normal RelA acetylation. The p50/RelA which translocates to the nucle-
us either in primary cortical neuronal cultures exposed to precondition-
ing OGD, as well as in cortices of mice subjected to preconditioning
MCAo, showed a general deacetylation. Conversely, RelA activated
after noxious ischemia displayed a general deacetylation associated
with a site-specific acetylation on the K310 residue. The relevance of
K310 acetylation to RelA-mediated effects during ischemiawas demon-
strated bymutagenesis analysis. The substitution of lysinewith arginine
at the RelA 310 residue impaired the acetylation at this site. In cells ex-
pressing the mutated RelA subunit, the OGD-mediated dmt1 (divalent
metal trasporter-1) transcription [67] as well as the cell damage were
totally prevented [94]. It suggested that a mismatch between “general”
and “site-specific” (K310) acetylation of RelA, could be responsible for
deleterious effects of NF-kB in brain ischemia. By undergoing such aber-
rant acetylation, RelA detached from the anti-apoptotic Bcl-xL gene pro-
moter to bind the pro-apoptotic Bim gene promoter. The RelA binding
was specifically followed by promoter–associated histone acetylation
[95] . In spite of changing the acetylation state of RelA, lethal ischemia
produced a significant reduction of global H3 histone acetylation [95],
in line with previous evidence [35]. We found that treatments with
MS-275 (HDAC1-3 inhibitor) and resveratrol (AMPK/SIRT1 activator)
in the post-ischemic period, corrected the aberrant RelA acetylation
and displayed a significant neuroprotective activity [95]. MS-275 and
resveratrol in combination showed a long-lasting efficacy and a wide
therapeutic window. Their beneficial effects were still evident 72 h
after the MCAO and when administered within 7 h from the ischemic
onset. Besides correcting the aberrant RelA acetylation, the combination
of MS275 and resveratrol displayed a concerted effect on H3 histones
acetylation. The drugs produced a shift of RelA binding from the Bim
to the Bcl-xL promoter followed by a concomitant acetylation of H3 his-
tones associated with the Bcl-xL promoter.
While the RelA acetylation on microglia activation and polarization
in brain ischemia has not been investigated yet, it has been proved to
play a role in the microglia activation and microglia-dependent neuro-
toxicity in mixed neuron/glial cultures exposed to amyloid-β. In line
with previous data [9], Aβ stimulated NF-κB inmicroglia and astrocytes
[19]. The Aβ-induced neuronal toxicitywas strictly dependent onNF-κB
activation in microglia, through the acetylation at the Lys310 RelA. Ei-
ther microglia-targeted overexpression of SIRT1, which specifically
deacetylated RelA at Lys310 [174], or pretreatment with the SIRT1 acti-
vator resveratrol, effectively decreased the levels of Ac-RelA, without af-
fecting total RelA content. Both treatments ultimately reduced
microglia-dependent neurotoxicity [19].
Whether the acetylation of RelA at Lys310 demonstrated in ischemic
brain has a relevance to theM1/M2 polarization of microglia remains to
be established. If this hypothesis will be confirmed, the epigenetic drug
combination, class I HDACi and resveratrol, might represent an innova-
tive therapeutic approach to modulate microglia polarization and drive
brain repair.
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